

STABILITY INDICATING HPTLC METHOD DEVELOPMENT AND VALIDATION FOR COMBINED DOSAGE FORM OF TOLPERISONE HYDROCHLORIDE AND DICLOFENAC SODIUM

PareshBavaliya*¹, Vijay Kalkani², Raval Kashyap³

¹Department of QA, Saurashtra University, Gujarat

²Asst. Proff., Department of Pharmacology, Noble Pharmacy College, Junagadh

³Asst. Proff.& Head, Department of QA, Noble Pharmacy College, Junagadh

ABSTRACT


A simple HPTLC method has been developed and subsequently validated for tablet dosage form. The method employed TLC aluminum plates precoated with silica gel 60F₂₅₄ as the stationary phase. The solvent system consist of Methanol: Toluene: Ethyl Acetate (2.5:7:0.5 v/v/v) and saturation time was 25 min. This system was found to give compact spots for diclofenac sodium ($R_f = 0.7 \pm$) and tolperisone hydrochloride ($R_f = 0.5$). Analysis of tolperisone hydrochloride, diclofenac sodium was carried out at 275nm. Linearity of diclofenac sodium and tolperisone hydrochloride was found to be $y = 5.3727x + 4514.2$, $R^2 = 0.998$, $y = 9.376x + 2635.6$, $R^2 = 0.995$ respectively in concentration range of 300-1500 $\mu\text{g}/\text{band}$ and 100-300 $\mu\text{g}/\text{band}$. % Assay of tolperisone hydrochloride and diclofenac sodium was found to be 99.16% w/v and 99.60 % w/v. Results of all other experiments for method validation were found within the specified criteria of ICH guideline.

Key words: Tolperisone, HCL, Diclofenac Sodium, Validation Parameter


INTRODUCTION

Tolperisone Hydrochloride is approved by FDA as a generic drug manufacturing for regulatory market and non-regulated market to Taj Pharmaceuticals, Mumbai on 7th October 2010. It is piperidine derivative centrally acting muscle relaxant drug. Generic formulations of this drug are available in market now. Tolperisone acts at the level of spinal cord by blocking sodium channels and calcium channels. It exerts spinal reflex inhibitory action predominantly via a pre synaptic inhibition of the transmitter release from the primary afferent endings via a combined action on voltage-gated sodium and calcium channels. It causes preferential antinociceptive activity against thermal

stimulation that is likely to be attributed to its local anesthetic action. It is well absorbed in the stomach, duodenum and jejunum. It contains the following structure:



Its IUPAC name is 1-(4-methylphenyl)-2-methyl-3-(1-piperidino)propanone hydrochloride. Its molecular weight and molecular weight are $C_{16}H_{23}NO \cdot HCl$ & 281.82 g/mole respectively. It is very soluble in acetic acid, freely soluble in acetone and water, soluble in acetic anhydride, slightly soluble in acetone, partially insoluble in diethyl ether. IUPAC name of Diclofenac sodium is Sodium{2-[(2,6-dichlorophenyl)amino]phenyl}acetate & its structure is defined as below:



Its molecular formula and molecular weight are $C_{14}H_{10}Cl_2NNaO_2$ & 318.13 g/mole. It is very slightly soluble in cold water, considerably more soluble in hot water, soluble in ethanol and ethyl acetate, very slightly soluble in chloroform, slightly soluble in ether, practically insoluble in petroleum ether, pentane and benzene.^[1-2] Up to now some analytical methods developed on Tolperisone, HCL & Diclofenac Sodium. But no stability indicating method developed by HPTLC & here developed method was validated by ICH guideline.^[3-25]

MATERIALS & METHODS:

Selection of Solvent:

Tolperisone HCl and Diclofenac sodium is freely soluble in the methanol. Hence, methanol is selected as solvent for both the drug.

Selection of Wavelength for Detection:

The wavelength for detection was selected by taking UV spectra of drug. The wavelength which gives the best result for proposed method was found to be 255nm for Tolperisone HCl and 275 nm for Diclofenac sodium. These wavelengths were used for detection during whole method development.

Optimization of Mobile Phase:

Mobile phase was selected based on the review of literature and theoretical aspects. Various combinations of Methanol, Toluene, Acetone, Chloroform, Ethyl acetate, ammonia and Triethylamine (TEA) etc... were tried.

Table no1:List of Mobile Phase Trials in HPTLC

Sr. No.	Mobile phase composition	Result
1	Methanol	Tolperisone HCl was retained only
2	Toluene	Tolperisone HCl was retained only
3	Ethyl acetate	Drug spot was not found for Diclofenac sodium
4	Chloroform	Drug spot was not found Diclofenac sodium
5	Acetone	Drug spot was not found for Diclofenac Sodium
6	Methanol: Toluene (5:5 v/v)	Rf was more for Tolperisone HCl
7	Methanol: Toluene (8:2 v/v)	Rf was more for Diclofenac sodium
8	Methanol : Toluene (2:8 v/v)	Rf was proper but smiling effect was observed for both drugs
9	Methanol : Toluene: Ethyl Acetate (2:7:1 v/v/v)	Rf was proper but tailing was observed for Tolperisone HCl
10	Methanol : Toluene: Ethyl Acetate (3:6:1 v/v/v)	Rf was proper but tailing was observed for Tolperisone HCl
11	Methanol : Toluene: Ethyl Acetate (3:6.5:0.5 v/v/v)	Rf was more for Diclofenac sodium
12	Methanol : Toluene: Ethyl Acetate (2.5:7:0.5 v/v/v)	Rf value was proper for both the drugs

Sharp peak were appeared with R_f value of 0.5 for Tolperisone HCl and 0.7 for Diclofenac sodium by using Methanol: Toluene: Ethyl Acetate (2.5:7:0.5 v/v/v) and was selected as a mobile phase for the method

Optimization of Saturation Time:

Saturation time was optimized at five different time intervals that are 10 min, 15 min, 20min, 25min and 30 min the best results was obtained at 25 min.

PREPARATION OF SOLUTIONS:**Preparation of Mobile Phase:**

Mobile phase was prepared by mixing the components of Methanol: Toluene: Ethyl Acetate (2.5:7:0.5 v/v/v).

Preparation of Standard Stock Solution:

Weigh accurately 15mg of Tolperisone HCl and 5mg of Diclofenac sodium and transferred to 10 ml volumetric flask. Methanol (HPLC GRADE) was added to dissolve the drug and final volume was made with the same solvent to obtain a concentration 1500 µg/ml for Tolperisone HCl and 500 µg/ml for Diclofenac sodium, this solutions were used for analysis.

Preparation of Sample Solution:

Weigh powder equivalent to 15 mg of Tolperisone HCl and 5mg Diclofenac sodium transferred to 10 ml volumetric flask. Methanol (HPLC GRADE) was added to dissolve the drug and final volume was made with the same solvent to obtain a concentration 1500 µg/ml for Tolperisone HCl and 500 µg/ml for Diclofenac sodium and this solution was used for analysis.

HPTLC METHOD VALIDATION PARAMETERS:**Linearity:**

Linearity of Tolperisone HCl and Diclofenac sodium were performed over a concentration range of 300-1500µg/band and 100-500 µg/band for Tolperisone HCl and Diclofenac sodium respectively. 0.2, 0.4, 0.6, 0.8 and 1.0 µl of standard stock solution was applied to each band on TLC plate using Hamilton syringe by Linomat V Applicator. The detection was done at 255nm for Tolperisone HCl and Diclofenac sodium and the R_f value for Tolperisone HCl and Diclofenac sodium was found to be 0.5 and 0.7 respectively.

Accuracy:

Accuracy may often be expressed as % Recovery by the assay of known, added amount of analyte. It's measure of the exactness of the analytical method. The recovery experiments were carried out in triplicate by spiking previously analyzed samples of the Tolperisone HCl (300 µg/band) and Diclofenac sodium (100 µg/band) with three different concentrations of standards at 80%, 100% and 120% respectively.

Precision:**Repeatability:**

The final solution containing 600 µg/band of Tolperisone HCl and 200 µg/band of Diclofenac Sodium was prepared and injected 6 times into the column to get the densitogram. The peak area were measured of the densitograms and % RSD was calculated.

Intraday Precision:

For Intraday Precision, The final solution containing 600 µg/band of Tolperisone HCl and 200 µg/band of Diclofenac Sodium was prepared and injected 6 times into the column at 1hr, 2hr and 3hr to get the densitogram. The peak area were measured of the densitograms and % RSD was calculated.

Interday Precision:

For Interday Precision, The final solution containing 600 µg/band of Tolperisone HCl and 200 µg/band of Diclofenac sodium was prepared and injected 6 times into the column on different time interval; 1st day, 2nd day and 3rd day to get the densitogram. The peak area were measured of the densitograms and % RSD was calculated.

Assay:

Assay of dosage form is the one of critical quality parameter to assure the quality of dosage form. Some interference of the excipients with the peaks of interest appeared; hence the proposed is applicable for the routine estimation of Tolperisone HCl and Diclofenac sodium in pharmaceutical dosage forms. The method was successfully applied for the estimation of contents in the tablet. 600µg/band of Tolperisone HCl and 200 µg/band of Diclofenac sodium test sample were used for measurement of peak area and that was compare with peak area of standard.

Specificity:

The specificity of the method was determined by checking the interference of placebo with analyte. The densitograms of blank, mobile phase and placebo do not show any interference at the R_f of Tolperisone HCl and Diclofenac Sodium as it can be seen from respective densotigrams. Only one peak of Tolperisone HCl and Diclofenac Sodium were obtained in the spectral evaluation which indicates that there was no interference from excipients in the proposed method. Further, peak purity data clearly shows that there is no any other interference in the developed method.

Robustness:

It means some deliberate changes have been made to the method parameter and check any significant changes obtained in the results or not. If not than the method is robust. Here, in this HPTLC method chamber saturation time and wavelength were changed to check the robustness of the developed method. Results are expressed in terms of %RSD.

LOD & LOQ

It is the lowest amount of analyte in a sample that can be detected but not necessarily quantities under the stated experimental conditions. Limit of detection can be calculated using following equation as per ICH guidelines.

$$\text{LOD}=3.3\times\text{N}/\text{S}$$

It is the lowest concentration of analyte in a sample that can be determined with the acceptable precision and accuracy under stated experimental conditions. Limit of quantification can be calculated using following equation as per ICH guidelines.

$$\text{LOQ}=10\times\text{N}/\text{S}$$

Where, N is the standard deviation of the peak areas of the drug and S is the slope of the corresponding calibration curve.

DEGRADATION STUDIES:

All degradation studies were done at a drug concentration of 900 µg/band for Tolperisone HCl and 300µg/band for DiclofeancSodium.

Forced Degradation under Acidic Condition:

To 1 ml of stock solution, 1 ml of 1.0 N HCl was added in a 10 ml of volumetric flask and volume was brought up to the mark with methanol. The volumetric flask was kept under normal condition for 24 hours for degradation. After 24 hours, 1 ml of solution was withdrawn and neutralize with 1.0 N NaOH. Resulting solution was analyzed for acid degradation study.

Forced Degradation under Alkaline Condition:

To 1 ml of stock solution, 1 ml of 1 N NaOH was added in a 10 ml of volumetric flask and volume was brought up to the mark with methanol. The volumetric flask was kept under normal condition for 24 hours for degradation. After 24 hours, 1 ml of

solution was withdrawn and neutralize with 1 N HCl. Resulting solution was analyzed for alkaline degradation study.

Forced Degradation under Oxidative Condition:

To 1 ml of stock solution, 1 ml of 3 % hydrogen peroxide was added in a 10 ml of volumetric flask and volume was brought up to the mark with methanol. The volumetric flask was kept under normal condition for 24 hours for degradation. After 24 hours, solution was heated in a boiling water bath to remove excess hydrogen peroxide. Resulting solution was analyzed for oxidative degradation study.

Forced Degradation under Neutral Condition:

To 1 ml of stock solution, 1 ml of water (distilled) was added in a 10 ml of volumetric flask and volume was brought up to the mark with methanol. The volumetric flask was kept under normal condition for 24 hours for degradation. After 24 hours, Resulting solution was analyzed for neutral degradation study.

Forced Degradation under Thermal Condition:

For thermal decomposition drug powders were kept at 60°C for 48 hours. From that powder solution having concentration of 900 µg/band for Tolperisone HCl and 300 µg/band for Diclofenac sodium were prepared and analyzed for thermal degradation study.

Forced Degradation under Direct Sunlight:

A samples of drug were exposed to a direct sunlight. Drug were kept in petridis for time period of 48 hours. From that powder solution having concentration 900 µg/band for Tolperisone HCL and 300 µg/band for Diclofenac sodium were prepared and analyzed for thermal degradation study.

RESULT & DISCUSSION:

METHOD DEVELOPMENT (HPTLC)

Table no2: Optimized Chromatographic Condition for HPTLC

Chromatographic Parameters	Optimized Condition
Stationary phase	Precoated silica gel 60 F 254 aluminum sheets

Journal of Biological Science

Mobile phase composition	Methanol: Toluene: Ethyl Acetate (2.5:7:0.5 v/v/v)
Saturation time	25 minutes
Migration distance	80mm
Temperature	25-30 °C
Detection	255 nm for Tolperisone HCl and 275 nm for Diclofenac sodium
Band width	6mm
R _f value	For Tolperisone HCl=0.5 For Diclofenac Sodium=0.7




Figure no 1: HPTLC densitogram of Tolperisone HCl (600 µg/band) and Diclofenac Sodium (200 µg/band)

Method validation

Linearity

Linear response was obtained in concentration range of 300-1500 µg/ml for Tolperisone HCl and 100-500 µg/ml for Diclofenac Sodium by plotting calibration curve peak area versus concentration. The regression equation was found to be $y = 5.3727x + 4514.2$ and $R^2 = 0.9983$ and $y = 9.376x + 2635.6$ and $R^2 = 0.9956$. For Tolperisone HCl and Diclofenac Sodium respectively. The data for linearity clearly indicates that proposed method is Linear.

Journal of Biological Science




Fig. no 2: HPTLC Densitogram showing linearity of Tolperisone HCl and Diclofenac Sodium

Table no: 3 Linearity data of Tolperisone HCl by HPTLC

Sr.no.	Concentration(µg/ban d)	Area			Average.	SD
		L1	L2	L3		
1	300	6004	6001	6015	6006.66	7.37
2	600	7812	7910	7781	7834.33	67.33
3	900	9479	9423	9521	9474.33	49.16
4	1200	10965	10895	10854	10904.66	56.12
5	1500	12511	12458	12632	12533.66	89.18




Figure no 3: Calibration curve of Tolperisone HCl.

Journal of Biological Science

Table no 4: Linearity data of Diclofenac Sodium by HPTLC

Sr.no.	Concentration(µg/band)	Area			Average	SD
		L1	L2	L3		
1	100	3495	3480	3475	3483.33	10.40
2	200	4585	4512	4610	4569.00	50.92
3	300	5469	5510	5480	5486.33	21.22
4	400	6471	6541	6480	6497.33	38.08
5	500	7265	7135	7221	7207.00	66.12




Figure no 4: Calibration curve for Diclofenac NA Precision

Repeatability

Repeatability was done to check the difference between results under the same chromatographic condition. %RSD of Tolperisone HCl and Diclofenac Sodium was found to be **0.89** and **0.80**. All parameters are less than 2. This clearly indicates that proposed method is precise.

Table No 5: Repeatability data of Tolperisone HCl by HPTLC

Sr.No.	Concentration (µg/band)	Area
1	600	7732.66 ±69.24

*n=6

Table no 6: Repeatability data of Diclofenac Sodium by HPTLC

Sr.No.	Concentration ($\mu\text{g}/\text{band}$)	Area
1	200	4592.83 \pm 36.74

*n=6

Intraday Precision

% RSD for interday precision was found to be **1.35, 1.37, and 0.1.48** for Tolperisone HCl. and **1.17, 1.81 and 1.55** for Diclofenac Sodium. All parameters of % RSD are less than 2. This clearly indicates that proposed method is precise.

Table no 7: Intraday Precision of Tolperisone HCl by HPTLC

Sr. No.	Time Duration		
	1 st Hour (AU)	2 nd Hour (AU)	3 rd Hour (AU)
1	7711.66 \pm 104.59	7710.33 \pm 105.85	7681 \pm 113.78

*n=6

Table no 8: Intraday Precision of Diclofenac Sodium by HPTLC

Sr No.	Time Duration		
	1 st Hour (AU)	2 nd Hour (AU)	3 rd Hour (AU)
1	4662.33 \pm 54.81	4588.16 \pm 83.11	4621.66 \pm 71.94

*n=6

Interday Precision

% RSD for in interday precision was found to be **1.41, 1.18, and 1.45** for Tolperisone HCl. and **1.18, 1.42 and 1.16** for Diclofenac Sodium. All parameters are less than 2. This clearly indicates that proposed method is precise.

Table no 9: Interday precision data of Tolperisone HCl by HPTLC

Sr. No.	Time Duration		
	1 st Day (AU)	2 nd Day (AU)	3 rd Day (AU)
1	7831.33 \pm 111.16	7758.33 \pm 92.11	7772.83 \pm 112.90

*n=6

Journal of Biological Science

Table no 10: Interday precision data of Diclofenac Sodium by HPTLC

Sr. No.	Time Duration		
	1 st Day (AU)	2 nd Day (AU)	3 rd Day (AU)
1	4567.16±54.23	4593.66±65.67	4567±53.34

*n=6

Accuracy

Accuracy of method is express in terms of %recovery study at 80%,100 and 120% level of recovery of three replicate of each of both drug were determine and data of recovery was given in following table. Table 5.13 shows recovery from the synthetic mixture. The data shows that proposed method is accurate.

Table no 11: Accuracy data of Tolperisone HCl by HPTLC

Level of Recovery	Concentration (µg/band)		Total amt.	Area	Amount Recovered	% Recovery	Mean Recovery	Standard Deviation of area	%RSD of area
	Standard	test							
80%	240	300	540	7409	538.83	99.78	99.47	9.53	0.12
	240	300	540	7390	535.29	99.12			
	240	300	540	7401	537.34	99.50			
100%	600	300	900	7727	598.02	99.67	99.45	6.55	0.08
	600	300	900	7719	596.53	99.42			
	600	300	900	7714	595.60	99.26			
120%	360	300	660	8045	657.21	99.57	99.42	5.03	0.06
	360	300	660	8035	655.35	99.29			
	360	300	660	8039	656.09	99.40			

Table no 12: Accuracy data of Diclofenac Sodium by HPTLC

Level of Recovery	Concentration (µg/band)		Total amt.	Area	Amount Recovered	% Recovery	Mean Recovery	Standard Deviation of area	%RSD of area
	Standard	test							

Journal of Biological Science

80%	80	100	180	28025	178.12	98.95	98.61	8.38	0.029
	80	100	180	28010	176.40	98.00			
	80	100	180	28024	178.01	98.89			
100%	100	100	200	28225	199.46	99.73	99.37	7.63	0.027
	100	100	200	28220	198.93	99.46			
	100	100	200	28210	197.86	98.93			
120%	120	100	220	28405	218.67	99.39	99.60	3.78	0.017
	120	100	220	28412	219.42	99.73			
	120	100	220	28411	219.31	99.68			

LOD and LOQ

LOD and LOQ are calculated based on standard deviation and slope method and following result are found.

Table no 13: Data of LOD and LOQ by HPTLC

Drug	LOD($\mu\text{g}/\text{band}$)	LOQ($\mu\text{g}/\text{band}$)
Tolperisone HCl	19.22	57.66
Diclofenac Sodium	13.33	40.00

Robustness

Following data proves that proposed method is robustatsmall but deliberate change.

Table no 14: Data of robustness of Tolperisone HCl by HPTLC

Concentration (600 $\mu\text{g}/\text{band}$)	Wavelength (275 \pm 2)			Saturation time		
	275	273	277	25min	20min	30 min
1	7792.33 \pm 1 25.23	7648 \pm 8 4.65	7625.66 \pm 1 19.08	7792.33 \pm 1 25.23	7455.66 \pm 75.40	7482.33 \pm 78.21

*n=3

Table no 15: Data of robustness of Diclofenac Sodium by HPTLC

Concentration (200 $\mu\text{g}/\text{band}$)	Wavelength(275 \pm 2)			Saturation time		
	275	273	277	25min	20min	30 min
1	4565.33 \pm 69.51	4270 \pm 73 .13	4238.66 \pm 72.39	4565.33 \pm 69.51	4279.66 \pm 73.38	4203 \pm 71 .33

*n=3

Application of proposed method to the tablet dosage form

No interference of the excipients with the peaks of interest appeared; hence the proposed method is applicable for the routine estimation of Tolperisone HCl and Diclofenac Sodium in tablet dosage forms. Results obtained are shown in following table.

Table no 16: Assay of Tolperisone HCl and Diclofenac sodium in tablet dosage form by HPLTC

Formulation	Label claimed (mg)	Amount found(mg) per tablet	% Label claim
Tolperisone HCl	150	148.99±0.5	99.16±0.80
Diclofenac Sodium	50	49.58±0.3	99.6±0.62

Degradation study

Acidic decomposition

Tolperisone HCl is known to be acid liable drug, and undergoes 5.94% degradation by stress acidic condition. While on the other hand Diclofenac Sodium is stable under stress acidic condition because there is little decrease in intensity of standard drug area. The degradation peak was not found within 24 hrs.




Fig.no 5: HPTLC densitogram of Diclofenac sodium by acid degradation (24 hrs.)




Fig.no 6: HPTLC densitogram of Tolperisone HCl by acid degradation (24 hrs.)




Fig. no 7: HPTLC densitogram of Tolperisone HCl and Diclofenac sodium by acid degradation (24 hrs.)

Alkaline decomposition

Tolperisone HCl is known to be acid liable drug, and undergoes 10.11% degradation by stress alkali condition. While on the other hand Diclofenac Sodium is stable under stress alkali condition because there is little decrease in intensity of standard drug area. The degradation peak was not found within 24 hrs.




Fig. no 8: HPTLC densitogram of Diclofenac sodium by alkali degradation (24 hrs.)




Fig.no 9: HPTLC densitogram of Tolperisone HCl by alkali degradation (24 hrs.)




Fig. no 10: HPTLC densitogram of Tolperisone HCl and Diclofenac sodium by alkali degradation (24 hrs.)

Oxidative degradation

Tolperisone HCl is known to be acid liable drug, and undergoes 4.35% degradation by stress oxidation condition. While on the other hand Diclofenac Sodium is stable

under stress oxidation condition because there is little decrease in intensity of standard drug area. The degradation peak was not found within 24 hrs.




Fig. no 11: HPTLC densitogram of Diclofenac sodium by oxidation degradation (24 hrs.)




Fig. no 12: HPTLC densitogram of Tolperisone HCl by oxidation degradation (24 hrs.)




Fig. no 13: HPTLC densitogram of Tolperisone HCl and Diclofenac sodium by oxidation degradation (24 hrs.)

Thermal decomposition

Tolperisone HCl is known to be acid liable drug, and undergoes 2.93% degradation by stress oxidation condition. While on the other hand Diclofenac Sodium is stable under stress oxidation condition because there is little decrease in intensity of standard drug area. The degradation peak was not found within 24 hrs.




Fig. no 14: HPTLC densitogram of Diclofenac sodium by thermal degradation (24 hrs.)




Fig. no 15: HPTLC densitogram of Tolperisone HCl by thermal degradation (24 hrs.)




Fig. no 16: HPTLC densitogram of Tolperisone HCl and Diclofenac sodium by thermal degradation (24 hrs.)

Sunlight degradation

Both drugs are very stable under direct sunlight condition. There is no degradant peak in direct sunlight condition even after 24 hrs




Fig. no 17: HPTLC densitogram of Diclofenac sodium by sun light degradation (24 hrs.)




Fig. no 18: HPTLC densitogram of Tolperisone HCl by sun light degradation (24 hrs.)




Fig no 19: HPTLC densitogram of Tolperisone HCl and Diclofenac sodium by sun light degradation (24 hrs.)

Table no 17: Stability data of drug

Sr. No	Stress Type	% recovery of Tolperisone HCl	Deceased area of Diclofenac sodium	% degradation of Tolperisone HCl	% degradation Of Diclofenac Sodium
1	Acid	94.06	5345	5.94	-
2	Base	89.89	5240	10.11	-
3	Oxidation	95.65	5389	4.35	-
4	Thermal	97.07	5410	1.93	-
5	Sunlight	100	-	-	-

Tolperisone HCl was more degrade than Diclofenac Sodium in different stress condition. Diclofenac Sodium degrade significantly in alkaline condition. Tolperisone HCl degrade significantly in acidic, basic, oxidized and thermal condition.

CONCLUSION:

Review of literature reveals that no stability indicating HPTLC method reported for simultaneous estimation of Tolperisone HCl and Dcilofenac sodium in combined solid dosage form. So, the HPTLC method has been developed for simultaneous estimation of Tolperisone HCl and Dcilofenac sodium in combined tablet dosage

form. Simple, accurate, precise and reproducible method for simultaneous estimation of Tolperisone HCl and Diclofenac sodium in Tablet dosage form has been developed by HPTLC. The proposed method gives good resolution of Tolperisone HCl, Diclofenac Sodium and degradant product in degradation study. So, proposed method can be applied for routine quality control test.

REFERENCES:

1. Japanese Pharmacopoeia, Official Monographs, Tolperisone Hydrochloride, 15th Edn., 1190;
2. Diclofenac sodium: IP 2010
3. Carolin IN., Balan P., Chiranjeevi N., Maheswari VU., Karthikeyan M. "Method development, validation and forced degradation studies of tolperisone hydrochloride by RP-HPLC method in bulk and tablet dosage form" International journal of pharmacy and bio sciences 2011; 2(4):324-328
4. Chhalotiya UK, Bhatt KK, Shah DA, Nagda DC, Chauhan GR. "Estimation of centrally acting muscle relaxant drug tolperisone hydrochloride using HPTLC method. World journal of analytical chemistry 2013; 1(1):1-7
5. Dhola VV., Yadav SK., Sen AK., Zanwar A., Seth A. K., "The simultaneous estimation of tolperisone hydrochloride and diclofenac sodium in tablet dosage form by UV spectrophotometric methods" International journal of Pharmaceutical science and research 2013; 3(1), 286-295
6. Emami J., Ghassami N., Talari R. A., "Rapid and sensitive modified HPLC method for determination of diclofenac in human plasma and its application in pharmacokinetic studies, Tehran university of medical science" 2007; 15(3): 132-138
7. Gevriya B., Mashru RC. "Simultaneous estimation of diclofenac sodium and tolperisone hydrochloride in combined pharmaceutical formulation, International journal of pharmaceutical sciences" 2013 4(1), 322-327
8. Gohel N. Parmar V. K., "Spectrophotometric methods for simultaneous determination of tolperisone hydrochloride and diclofenac sodium in combined tablet dosage form" 2013 Inventirapid: pharmaceutical analysis and quality assurance ;2:663

9. Harde M.T., Punde A.P., Chaudhari PD “Simultaneous estimation of tolperisone hydrochloride and diclofenac sodium in bulk and tablet dosage form by RP-HPLC method” 2013 Journal of Pharmaceutical research;2(7):1-5
10. Hariyani KP, Patel SA., “Spectrophotometric estimation of tolperisone hydrochloride and diclofenac sodium in synthetic mixture by area under curve method, International journal of pharmaceutical and research science 2013;2(3):425-228.
11. Koladiya B. and Vaghela V. “.Development and validation of a RP-HPLC method for the estimation of tolperisone hydrochloride in bulk and Pharmaceutical dosage form International journal of advances in pharmaceutical analysis” 2012;2(10) :06-10
12. Mahaparale S. P., Shinde S. S., Nirmal P. N. “Simultaneous UV Spectrophotometric estimation of diclofenac and tolperisone hydrochloride in tablet dosage form, international journal of research and development in pharmacy and life sciences” 2013; 2(5):574-579
13. Moffat, A.C., Osselton, M.D., Widdop, B., “Clark’s Analysis Of Drugs And Poisons In Pharmaceuticals, Body Fluids And Postmortem Materials, Part-II, 3rdEd.. 2004; The Pharmaceutical Press.Pp.500.
14. Pai N. R., Sawant S.S., “Development and validation of RP-HPLC method for determining impurity profiling for tolperisone hydrochloride in tablet dosage form Journal of current chemistry and pharmaceutical sciences” 2013;3(4):243-254.
15. Patel D. S., Captain A. D., Prajapati P. P., Shah H. G. “Development and validation of HPTLC method for simultaneous determination of tolperisone hydrochloride and diclofenac sodium in combined dosage form, international journal of pharmtechnology and research” 2013; 5(1):147-154
16. Patel H. H., Patel P.U., “Development and validation of RP-HPLC method for simultaneous determination of tolperisone hydrochloride and diclofenac sodium in synthetic mixture.international journal of universal pharmacy and life sciences” 2013; 3(2):102-110
17. Shah A., Patel P., Patel A., “Development and validation of simultaneous equation spectrophotometric method for simultaneous estimation of tolperisone hydrochloride and diclofenac sodium in their combined tablet

- dosage form, international journal of pharmacy and pharmaceutical sciences ;4(5):501-505.
18. Stephen, G., Schulman, B.S., Vogt, J.W., Munson, "High Performance Liquid Chromatography: Theory" Instrumentation and Practice of Application. Part B: Pp.15 - 108.
 19. Solanki A.S., Mathew M., Puthusseri S. "Development and validation of UV spectrophotometric methods for simultaneous estimation of tolperisone hydrochloride and diclofenac sodium in tablet dosage form" 2013 international journal of pharmacy and biological science ;3(4) :42-48
 20. Stephen, G., Schulman, B.S., Vogt, J.W., Munson, "High Performance Liquid Chromatography: Theory, Instrumentation and Practice of Application. 2001 Part B: Pp.15 - 108..
 21. Vaghasia S., Jani A., "Development and validation of spectrophotometric area under curve method for simultaneous estimation of tolperisone hydrochloride and diclofenac sodium in their combined tablet dosage form" international journal of pharmacy and pharmaceutical sciences 2013;5(4):214-219
 22. Vasavi A., Visagaperumal D., "Development and validation of RP-HPLC method for simultaneous estimation of eperisone hydrochloride and diclofenac sodium in pharmaceutical dosage form" journal of advanced pharmacy education and research 2013;4(3):550
 23. Venkata R. V., Sharma P. "RP-HPLC Method development and validation for simultaneous estimation of diclofenac and tolperisone in tablet dosage form"asian journal of pharmaceutical and clinical reaserch2013;6(3):186-189
 24. Vyas V. L., Chaudhary A.B., Mohan S., "Simultaneous determination of tolperisone hydrochloride and diclofenac sodium in tablet by RP-HPLC" inventi rapid: pharmaceutical analysis and quality assurance 2013;2(1): 85-90
 25. ICH Guidelines, Validation of Analytical Procedure Methodology, Q2b, (1996), ICH Harmonized Tripartite Guideline